RocRock Bio and Porton Bio, two biotech companies, teamed up in Suzhou on March 19, 2024, to advance the clinical development of RocRock Bio's lead candidate, RR-M01, through a strategic partnership focused on its Investigational New Drug (IND) application. The ceremony was attended by RocRock Bio's founder, Xiushan Yin, and Porton Bio's CEO, Rong Tao.
RocRock Bio has been at the forefront of macrophage-based cancer therapy research. In 2023, in collaboration with the Affiliated Hospital of Xuzhou Medical University, it initiated an Investigator Initiated Trial (IIT) for RR-M01, successfully administering the drug to the first patient. This trial demonstrated RR-M01's favorable safety profile and promising efficacy, particularly in treating recurrent and refractory ovarian cancer. Building on this success, RR-M01's therapeutic scope has expanded to include all solid tumors with HER2 positivity or low expression. The pipeline received ethical approval from the hospital in March 2024 and aims to recruit 20 patients this year.
Porton Bio, a leading contract development and manufacturing organization (CDMO) for gene and cell therapies, offers comprehensive services across plasmid, viral vector, cell and gene therapy, and nucleic acid therapy. This collaboration will enable RocRock Bio to expedite RR-M01's IND application by leveraging Porton Bio's expertise and resources, bringing new hope to patients with recurrent and refractory solid tumors.
(Negotiation for the signing ceremony)
From July 7 to 10, 2024, RocRock Bio and the SDMU China delegation visited Armenia, a Belt and Road nation. They focused on Mediterranean fever rare disease prevention and treatment, reaching cross-country rare disease project cooperation intentions. The visit aimed to use the Belt and Road policy to bring advanced Chinese medical technology to Armenia, enhancing local healthcare.
The delegation included RocRock Bio founder and CEO Xiushan Yin and SDMU professor Jinxiang Han. They were received by Armenian officials such as Health Minister Avanesyan, Deputy Health Minister Nanushyan, International Relations Minister Armen, Chinese Ambassador Fan Yong, and Armenian National Academy of Sciences President Ashot Saghyan.
Porton co-founder and Porton Bio CEO Tao Rong expressed: "I'm thrilled to partner with RocRock, a leader in macrophage - based drug development. Their third-generation CAR-M drug, RR-M01, successfully dosed the first patient in a global clinical trial last year. Our shared goal is to expedite the clinical trial registration of this promising pipeline to bring hope to cancer patients. With our international standards, rigorous design, quality management, and project experience, Porton Bio is committed to supporting RocRock's new drug development. Together, we aim to fast-track RocRock's CAR-M drug development, making a positive impact on public health."
(Group photo at the signing ceremony)
Offline Website Builder